MEK

MEK is a member of the MAPK signaling cascade that is activated in melanoma. When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

Cat. No.	Product name	CAS No.	Purity
T6419	BMS-536924	468740-43-4	99.19%
T6419	BMS-536924 (BMS 536924) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for ...
T6039	TAK-285	871026-44-7	99.17%
T6039	TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Auro...
T6077	ZM-447439	331771-20-1	99.11%
T6077	ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective f...
T2443	CI-1040	212631-79-3	99.1%
T2443	CI-1040 (PD 184352) (PD184352) is an ATP non-competitive MEK1/2 inhibitor (IC50: 17 nM).
T21635	PD184161	212631-67-9	99.09%
T21635	PD184161 is a novel, orally-active MEK inhibitor. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner[1].
T5S2361	Epiberberine	6873-09-2	98.95%
T5S2361	1. Epiberberine may be caused drug interactions based on CYP2D6 enzyme. 2. Epiberberine has anti-adipogenic effect is mediated by downregulation of the Raf/MEK1/...
T6843	GDC-0623	1168091-68-6	98.95%
T6843	GDC-0623 (RG 7421) is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
TN1459	Bufarenogin	17008-65-0	98.77%
TN1459	Bufarenogin (3beta,12beta,14-Trihydroxy-11-oxo-5beta-bufa-20,22-dienolide) is a bufadienolide isolated from parotoid gland secretions of the Cuban endemic toad P...
T6218	Selumetinib	606143-52-6	98.73%
T6218	Selumetinib (AZD6244) (AZD6244) is an effective, specific inhibitor of MEK1 and ERK1/2 phosphorylation (IC50: 14/10 nM).
T6083	AZD8330	869357-68-6	98.72%
T6083	AZD8330 (ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.
T6223	U0126-EtOH	1173097-76-1	98.65%
T6223	U0126-EtOH (U0126 Ethanol) is a non-ATP competitive specific inhibitor of MEK1/2 (IC50: 0.07/0.06 μM).
T6760	APS-2-79 hydrochloride	2002381-31-7	98.64%
T6760	APS-2-79 hydrochloride (APS-2-79 HCl) is a MAPK antagonist that modulating KSR-dependent MAPK signalling by antagonizing RAF heterodimerization as well as the co...
T2623	PD98059	167869-21-8	98.52%
T2623	PD98059 is an MEK inhibitor that inhibits MEK1 and MEK2 (IC50=2/50 μM) and is non-ATP-competitive. PD98059 is also antagonistic as a ligand for AHR. PD98059 inhi...
T27242	EF24	342808-40-6	98.47%
T27242	EF24 (3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone) treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of M...
T2327	Pelitinib	257933-82-7	98.37%
T2327	Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
TN1819	Kaempferol 3-neohesperidoside	32602-81-6	98.34%
TN1819	Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside), a flavonoid compound, demonstrates an insulinomimetic effect on the rat soleus muscle.
T6971	Ro 5126766	946128-88-7	98.3%
T6971	RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1.
T5412	RO4987655	874101-00-5	98.21%
T5412	RO4987655 (RG7167) is an orally active and highly selective MEK inhibitor (IC50: 5.2 nM for MEK1/MEK2).
T6131	Pimasertib	1236699-92-5	98.15%
T6131	Pimasertib (AS703026) is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
T2508	Binimetinib	606143-89-9	98.03%
T2508	Binimetinib (ARRY-162) (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay.